Hussain Sabena F, Miller Elyse, Aljohani Othman, Auerbach Scott, Bearl David, Benvenuto Victor, Bonura Erica, Crawford Richard L, Joong Anna, Dyal Jameson, Hartje-Dunn Christina, Jana Sujit, Kaushal Sonia, Lynn Melanie, Spinner Joseph, Radel Laura, Raskin Alexander, Torpoco-Rivera Diana, Wilkens Sarah J, Villa Chet R
Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Benioff Children's Hospitals, San Francisco, California.
JHLT Open. 2024 Dec 19;7:100198. doi: 10.1016/j.jhlto.2024.100198. eCollection 2025 Feb.
Patients with congenital heart disease (CHD) frequently have had valve interventions, including replacement with a mechanical valve (mechV). The impact of a mechV on clinical outcomes in patients undergoing ventricular assist device (VAD) implantation is not well characterized.
This study assessed VAD outcomes in patients with CHD and a mechV.
All patients with a history of CHD ( = 433) in the Advanced Cardiac Therapies Improving Outcomes Network database were included in the study (January 2012-January 2023). Patient characteristics and outcomes were assessed among patients with a mechV and without a mechV.
Twenty-seven (6%) patients with CHD had a mechV at VAD implantation. Fourteen (52%) of the patients with mechV had univentricular anatomy and 13 (48%) had biventricular anatomy. Patients with mechV were older (4.9 vs 1.9 years, = 0.02), smaller (14.9 vs 10.6 kg, = 0.02), and had a higher interagency registry for mechanically assisted circulatory support profile ( = 0.01). Three (11%) patients with mechV experienced a valve-related complication. There was no difference in survival ( = 0.4) or ischemic stroke frequency (11% vs 13%, = 1) between patients with mechV and non-mechV. Patients with mechV had higher frequency of hemorrhagic stroke (18% vs 4.7%, = 0.01) and major bleeding (44% vs 26%, = 0.04).
Patients with CHD with a mechV have similar survival to patients with non-mechV; however, there is higher risk of bleeding including hemorrhagic stroke.
先天性心脏病(CHD)患者经常接受瓣膜干预,包括机械瓣膜置换(mechV)。机械瓣膜对接受心室辅助装置(VAD)植入患者临床结局的影响尚未得到充分描述。
本研究评估了患有CHD并植入mechV患者的VAD结局。
纳入高级心脏治疗改善结局网络数据库中所有有CHD病史(n = 433)的患者(2012年1月至2023年1月)。在有mechV和无mechV的患者中评估患者特征和结局。
27例(6%)CHD患者在VAD植入时有mechV。有mechV的患者中14例(52%)为单心室解剖结构,13例(48%)为双心室解剖结构。有mechV的患者年龄较大(4.9岁对1.9岁,P = 0.02),体型较小(14.9 kg对10.6 kg,P = 0.02),且机械辅助循环支持概况的机构间注册评分较高(P = 0.01)。3例(11%)有mechV的患者发生瓣膜相关并发症。有mechV和无mechV的患者在生存率(P = 0.4)或缺血性卒中发生率(11%对13%,P = 1)方面无差异。有mechV的患者出血性卒中发生率(18%对4.7%,P = 0.01)和大出血发生率(44%对26%,P = 0.04)较高。
患有CHD并植入mechV的患者与无mechV的患者生存率相似;然而,包括出血性卒中在内的出血风险更高。